BioPharma Resources

Company · AMGN

Amgen

Includes drugs filed under related and acquired sponsor names. Trials are searched under: Amgen; Horizon Therapeutics Ireland DAC; Onyx Therapeutics, Inc..

Last checked: Nov 19, 2026Source: Drugs@FDA, ClinicalTrials.gov

NDAs and BLAs

40

31 still marketed

Novel approvals

20

Approvals since 2021

41

Originals and new uses

Phase 3 trials

311

Registered, any status

Trials by phase

All registered drug and biologic trials with this lead sponsor, any status. A public view of the pipeline.

Recent approvals

Originals and efficacy supplements, newest first.

Drugs in development (18)

Investigational drugs, not yet FDA-approved, in this company's active or recent Phase 2 and 3 trials. Phase 3 first.

Open in pipeline
  • Maridebart cafraglutideAMG 133Phase 314 trials

    Amgen · Obesity, Overweight, Obstructive Sleep Apnea

  • AmrubicinJapan onlyPhase 34 trials

    Gilead Sciences · Small Cell Lung Cancer, Extensive Stage Small Cell Lung Cancer (ES-SCLC), Small Cell Lung Cancer (SCLC)

  • DazodalibepVIB 4920, MEDI 4920Phase 33 trials

    Amgen · Sjögren's Syndrome (SS), Sjögren's Syndrome, Sjogren's Syndrome

  • OlpasiranAMG 890Phase 33 trials

    Amgen · Cardiovascular Disease, Atherosclerotic Cardiovascular Disease

  • RocatinlimabAMG 451Phase 33 trials

    Amgen · Atopic Dermatitis

  • ABP 206Phase 32 trials

    Amgen · Melanoma

  • ABP 234Phase 32 trials

    Amgen · Early-stage Non-squamous Non-small Cell Lung Cancer (NSCLC), Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer

  • BisphosphonatePhase 32 trials

    Ultragenyx Pharmaceutical Inc · Osteogenesis Imperfecta

  • XaluritamigAMG 509Phase 32 trials

    Amgen · Metastatic Castration-resistant Prostate Cancer

  • ABP 692Phase 31 trial

    Amgen · Relapsing-remitting Multiple Sclerosis (RRMS)

  • ABP 938Phase 31 trial

    Amgen · Neovascular Age-related Macular Degeneration, nAMD

  • BemarituzumabPhase 31 trial

    Amgen · Gastric Cancer, Gastroesophageal Junction Adenocarcinoma

  • Amgen · Melanoma

  • Amgen · Melanoma

  • AnvumetostatAMG 193Phase 23 trials

    Amgen · Advanced MTAP-null Solid Tumors, MTAP-deleted NSCLC, MTAP-null Non-Small-Cell Lung Cancer

  • AMG 732Phase 22 trials

    Amgen · Thyroid Eye Disease

  • DaxdilimabHZN-7734Phase 21 trial

    Amgen · Idiopathic Inflammatory Myositis

  • IDE397Phase 21 trial

    Amgen · MTAP-null Non-Small-Cell Lung Cancer, MTAP-null Solid Tumors

Recruiting Phase 3 trials

Largest first.

Marketed drugs (31)

Newest FDA action first.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.